Clinical Trial Update: Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

Phase 2 study of CM313 given as a subcutaneous injection for primary immune thrombocytopenia is currently active but not recruiting. The trial sponsor is Keymed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• CM313

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Primary Immune Thrombocytopenia | Phase 2 | Status: ACTIVE_NOT_RECRUITING